scPharmaceuticals (SCPH)

Company Profile

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company's lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA.

Company profile

Ticker

SCPH

Exchange

NASDAQ

Website

www.scpharmaceuticals.com

CEO

John Tucker

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001604950

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

scPharmaceuticals Securities Corporation ...

SCPH stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$18.67

Low target

$13.00

High target

$25.00

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

19 Dec 22

424B5

Prospectus supplement for primary offering

Free writing prospectus

22 Nov 22

424B5

Prospectus supplement for primary offering

9 Nov 22

Entered into a secured debt financing agreement for up to $100 million with funds managed by Oaktree

9 Nov 22

8-K

Entry into a Material Definitive Agreement

14 Oct 22

8-K

Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act

9 Aug 22

Transcripts

SCPH

Earnings call transcript

2022 Q3

12 Nov 22

Latest ownership filings

View all

Change in insider ownership

RA CAPITAL MANAGEMENT, L.P.

15 Aug 22

Financial summary

Financial statements Chart SCPH financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	41.47 mm	41.47 mm	41.47 mm	41.47 mm	41.47 mm	41.47 mm
Cash burn (monthly)	(no burn)	3.17 mm	3.33 mm	2.78 mm	2.73 mm	2.49 mm
Cash used (since last report)	n/a	12.91 mm	13.57 mm	11.33 mm	11.13 mm	10.13 mm
Cash remaining	n/a	28.56 mm	27.90 mm	30.14 mm	30.34 mm	31.34 mm
Runway (months of cash)	n/a	9.0	8.4	10.8	11.1	12.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

SCPH institutional ownership history Ownership history

62.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	39	39	–
Opened positions	4	4	–
Closed positions	4	3	+33.3%
Increased positions	9	16	-43.8%
Reduced positions	15	10	+50.0%

13F shares	Current	Prev Q	Change
Total value	201.52 mm	93.65 mm	+115.2%
Total shares	17.26 mm	18.95 mm	-8.9%
Total puts	12.60 k	0.00	NEW
Total calls	13.40 k	0.00	NEW
Total put/call ratio	0.9	–	–

Largest owners	Shares	Value	Change
Orbimed Advisors	4.80 mm	$31.28 mm	0.0%
5AM Venture Management	3.33 mm	$21.74 mm	-6.4%
5AM Ventures IV	3.25 mm	$17.21 mm	0.0%
Armistice Capital	2.49 mm	$16.25 mm	-7.7%
AIGH Capital Management	757.06 k	$4.94 mm	-43.8%
Vanguard	616.56 k	$4.02 mm	0.0%
Ikarian Capital	479.38 k	$3.13 mm	-45.8%
Worth Venture Partners	188.52 k	$1.23 mm	-43.9%
Renaissance Technologies	180.29 k	$1.18 mm	-5.9%
Dimensional Fund Advisors	139.12 k	$906.00 k	+19.5%

Largest transactions	Shares	Bought/sold	Change
AIGH Capital Management	757.06 k	-589.66 k	-43.8%
Ikarian Capital	479.38 k	-404.63 k	-45.8%
5AM Venture Management	3.33 mm	-226.62 k	-6.4%
Armistice Capital	2.49 mm	-208.00 k	-7.7%
Worth Venture Partners	188.52 k	-147.46 k	-43.9%
Belvedere Trading	120.71 k	-118.51 k	-49.5%
J. Goldman & Co	50.63 k	+50.63 k	NEW
Boothbay Fund Management	40.75 k	-44.71 k	-52.3%
Simplex Trading	21.22 k	-38.70 k	-64.6%
Group One Trading	27.06 k	+25.74 k	+1946.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SCPH insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Jan 23	Tucker John H	Common Stock	Grant	Acquire A	No	No	6.14	66,665	409.32 k	145,589
19 Jan 23	Tucker John H	Stock Option Common Stock	Grant	Acquire A	No	No	6.14	100,000	614.00 k	100,000
15 Dec 22	Rachael Nokes	Stock Option Common Stock	Grant	Acquire A	No	No	6.48	85,750	555.66 k	85,750
25 Nov 22	Orbimed Advisors	Common Stock	Buy	Acquire P	Yes	No	5.25	762,380	4.00 mm	5,328,328
10 Oct 22	5AM Partners IV	Common Stock	Sell	Dispose S	Yes	No	4.09	87,036	355.98 k	410,268
10 Oct 22	5AM Partners IV	Common Stock	Sell	Dispose S	Yes	No	4.09	19,017	77.78 k	92,983
10 Oct 22	5AM Partners IV	Common Stock	Sell	Dispose S	Yes	No	4.09	456,413	1.87 mm	2,231,601
7 Oct 22	Tucker John H	Common Stock	Payment of exercise	Dispose F	No	No	4.98	10,288	51.23 k	78,924
7 Oct 22	Tucker John H	Common Stock	Option exercise	Acquire M	No	No	0	42,250	0.00	89,212
7 Oct 22	Tucker John H	Stock Option Common Stock	Grant	Acquire A	No	No	3.25	42,250	137.31 k	42,250